Results 111 to 120 of about 24,724 (196)

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents. [PDF]

Ther Adv Hematol
Zeidan AM, Zhao R, Tepsick JG, Lan Z, Salimi T.   +4 more
europepmc   +1 more source

REST-driven upregulation of SFXN3 promotes AML progression via Wnt/β-catenin activation and confers decitabine resistance. [PDF]

Transl Oncol
Wang X, Huang Y, Sun M, Cai S, Hu X, Zheng Y, Fang S, Li S, Tu Y, Tang H.   +9 more
europepmc   +1 more source

The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. [PDF]

Ann Hematol
Luo C, Zhang J, Huang X, Wu G, Huang Y, Ding Y, Huang Z, Song Q, Chen J, Li X, Xu S.   +10 more
europepmc   +1 more source

Retraction Note: Hypoxia impairs decitabine-induced expression of HLA-DR in acute myeloid leukaemia cell lines. [PDF]

Clin Epigenetics
Humphries S, Burnard SM, Eggins CD, Keely S, Bond DR, Lee HJ.   +5 more
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source

Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country. [PDF]

Leuk Res Rep
Nguyen HT, Bach QK, Nguyen QN, Nguyen VN, Nguyen TVA, Pham-The H.   +5 more
europepmc   +1 more source

Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series. [PDF]

Front Oncol
Li Q, Ji J, Wu Y.
europepmc   +1 more source

Prognostic value of BTG1 for predicting decitabine sensitivity in <i>de novo</i> acute myeloid leukemia. [PDF]

iScience
Zhang S, Li M, Xu B, Zhu X, Mao X, Zhou H, Tong X, Su S, Zhu Y, Zhang D.   +9 more
europepmc   +1 more source

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial. [PDF]

Cancers (Basel)
Handa S, Koenig K, Zhao Q, Mims AS, Vasu S, Garzon R, Haque T, Benson D, Klisovic RB, Marcucci G, Walker AR, Bhatnagar B.   +11 more
europepmc   +1 more source

Combining drugs that bypass p53 to treat TP53-mutated leukemias. [PDF]

Blood Adv
Biswas S, Zahran ZAM, Gu X, Cardone L, Marti R, Mouannes N, Stich M, Jain A, Fedorov K, Tomlinson B, Goldfinger M, Verma A, Saunthararajah Y.   +12 more
europepmc   +1 more source